Favorable policies for Sino-foreign cooperation in biomedicine are flourishing

The bio-industry has been listed as one of the seven strategic emerging industries in my country, and its support has been continuously strengthened. Multinational pharmaceutical giants have spotted this and have shown a keen interest in China's bio-pharmaceutical industry. Joining forces between China and foreign countries to jointly create innovative biopharmaceuticals has become a new landscape in China's biomedical industry in 2012.
     Yesterday, the 2012 Biological Industry Cooperation Forum opened in Suzhou. Nearly 400 global biotech and pharmaceutical companies, Chinese biotech companies and venture capitalists, including Roche, Bayer, Eli Lilly, AstraZeneca, Legend Capital, etc. participated This forum.
     During the forum, the reporter learned that the main directions of the new round of international cooperation in the bio-industry include candidate new drugs, innovative drug development technologies, and corporate strategies.
     The strengthening of cooperation between China and foreign countries in biomedicine is mainly due to the favorable policy environment China has created for the biological industry. According to Dr. Xu Xiaoxing, head of China and Southeast Asia of Roche’s Global Cooperation Department, introduced to the Shanghai Securities News that the bio-industry has been listed by the Chinese government as one of the seven strategic emerging industries, and actively supports industrial transformation and increased support for the bio-industry. Make China's biological industry usher in a round of development opportunities. According to reports, Roche has been actively looking for partners recently, hoping to achieve a strong alliance and make breakthroughs in the domestic and international markets. "In addition to the usual business cooperation, Roche also looks forward to conducting research and development cooperation on the basis of patents, and has also conducted in-depth discussions with some interested listed companies, hoping to make progress as soon as possible." Xu Xiaoxing revealed.
     According to Dr. Xu Min, CEO of Paige Biopharmaceutical Co., Ltd., the Chinese government has strengthened its support for biomedicine in both the "Eleventh Five-Year" and "Twelfth Five-Year" periods. However, China's current pharmaceutical R&D is still in its infancy, at least 20-30 years behind Western biomedicine. Most of them are generic drugs. The average cost of new drug development accounts for only 2%, and the development of innovative drugs is still rare. Cooperating with multinational pharmaceutical giants will help expand the market, increase sales, obtain higher profits, and increase R&D investment; at the same time, it can also attract professionals to jointly develop new drugs and reduce risks.
     It is understood that in recent years, obtaining new drugs through R&D and technical cooperation has become an industry development trend, and cooperative transactions have also become an important part of China's biomedical industry. For the majority of domestic biopharmaceutical companies that are in their infancy, there is an urgent need to cooperate with well-known international pharmaceutical companies. At the same time, with the increasingly severe investment environment in the western biomedical industry, China's investment and market opportunities have also attracted the attention of large international pharmaceutical companies and investors. “The two sides are currently carrying out in-depth face-to-face communication and discussion to achieve technical and financial cooperation.” said the relevant person in charge of the Suzhou Industrial Park Bio-Industry Company, one of the organizers of the 2012 Bio-Industry Cooperation Forum.
     "There are about 5,000 pharmaceutical companies in my country, but none of them have been listed in overseas markets. Sino-foreign cooperation can play a positive role in this regard." Dr. Yu Qiang, President of Shengli Tech Biomedical Technology Co., Ltd. Look at the significance of cooperation between Chinese and foreign pharmaceutical companies. Through cooperation, the channel resources of multinational pharmaceutical companies can be borrowed to expand overseas market share, which will have a huge incentive effect for Chinese pharmaceutical companies.
     The financing channels of China Pharmaceuticals (600056, stocks) companies are not broad and free, which is another practical factor that encourages them to cooperate with foreign pharmaceutical companies. According to Dr. Xu Min, CEO of Pego Biomedical Co., Ltd., the US GEM supports the listing of biomedical companies that are not yet profitable, and the public market supports the development of bio-enterprises. In China, these companies can only rely on some industrial funds, venture capital and venture capital funds. They cannot accompany a company to go on forever, and the financial strength of Chinese biomedical companies is not enough to support the research and development of innovative drugs. Joint development has become a reality.